title: Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial.
abstract: BACKGROUND
  Sclerotherapy has been widely recommended as initial treatment for prevention of variceal rebleeding. The present study was aimed at comparing the efficacy of endoscopic sclerotherapy and long-term administration of propranolol in the prevention of rebleeding and long-term survival in patients who had bled from varices.
  
  
  METHODS
  One hundred sixteen consecutive cirrhotic patients admitted because of variceal bleeding were randomly allocated to either continuous administration of propranolol to reduce the resting heart rate by 25% (58 patients) or weekly intravariceal sclerotherapy sessions using 5% ethanolamide oleate until varices disappeared (58 patients). Results were analyzed on an intention-to-treat basis.
  
  
  RESULTS
  Rebleeding occurred in 37 patients of the propranolol group and in 26 patients of the sclerotherapy group (RR = 1.45; 95% CI, 1.03-2.03). The actuarial probability of rebleeding was lower in the sclerotherapy group (P = 0.02). No differences were found in rebleeding index, hospitalization requirements, survival, and causes of death. Complications were significantly more frequent and severe in the sclerotherapy group.
  
  
  CONCLUSIONS
  Despite the higher efficacy of sclerotherapy decreasing the probability of rebleeding when compared with propranolol, no beneficial effects were observed on other parameters also reflecting the efficacy of therapy. Moreover, complications of sclerotherapy were more frequent and severe than those of propranolol, which probably shall restrict the use of long-term elective sclerotherapy.
authors.affiliation: Gastroenterology Unit, Hospital Clinic i Provincial Medical School, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Terés
authors.forename: J
authors.initials: J
authors.lastname: Bosch
authors.forename: J M
authors.initials: JM
authors.lastname: Bordas
authors.forename: J C
authors.initials: JC
authors.lastname: Garcia Pagán
authors.forename: F
authors.initials: F
authors.lastname: Feu
authors.forename: I
authors.initials: I
authors.lastname: Cirera
authors.forename: J
authors.initials: J
authors.lastname: Rodés
mesh_terms: D000368:Aged; D004932:Esophageal and Gastric Varices / Q000401:mortality / Q000628:therapy*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use*; D011446:Prospective Studies; D012008:Recurrence; D015911:Sclerotherapy / Q000009:adverse effects; D015996:Survival Rate
chemical_list: D011433:Propranolol